Condition (MeSH)
Parathyroid Neoplasms
ClinicalTrials.gov lists 63 trials for Parathyroid Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
63 of the 63 trials are tagged with Parathyroid Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Parathyroid Neoplasms trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 4 |
| 2024 | 5 |
| 2023 | 4 |
| 2022 | 3 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 3 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Parathyroid Neoplasms trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 7 |
| Phase 2/3 | 2 |
| Phase 3 | 4 |
| Phase 4 | 3 |
| Not applicable | 16 |
| Observational | 21 |
| Expanded access | 1 |
How many Parathyroid Neoplasms trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 11 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 2 |
| Available | 1 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Parathyroid Neoplasms trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 4 |
| Amgen | 2 |
| Kyowa Kirin Co., Ltd. | 2 |
| Valerio Therapeutics | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Parathyroid Neoplasms? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cinacalcet | 3 |
| NIVOLUMAB | 2 |
| Belinostat | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 18F- fluorocholine | 1 |
| Dacarbazine and bortezomib | 1 |
| Lutetium-177 DOTATATE | 1 |
| Enitinostat | 1 |
| Acetaminophen 500Mg Cap | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Parathyroid Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypercalcaemia | 5 | 1 |
| Dyspnoea | 3 | 1 |
| Diarrhoea | 2 | 1 |
| Head and neck cancer | 2 | 1 |
| Lung neoplasm malignant | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Parathyroid Neoplasms? (42)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Assessing the feasibility of near infrared autofluorescence imaging in minimally-invasive video assisted parathyroidectomy and the autofluorescence signature of parathyroid adenomas. A single center surgical case series. | Surgical endoscopy | 2025 | Yes |
| Molecular and Clinical Spectrum of Primary Hyperparathyroidism. | Endocrine reviews | 2023 | Yes |
| Case Report: Nine-year-old with parathyroid adenoma within the piriform sinus. | Frontiers in endocrinology | 2023 | Yes |
| Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome. | The Journal of clinical endocrinology and metabolism | 2023 | Yes |
| Superior sensitivity of <sup>18</sup>F-fluorocholine: PET localization in primary hyperparathyroidism. | Surgery | 2022 | Yes |
Showing 5 of 42 publications.
Prevalence (54)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Parathyroid carcinoma | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Parathyroid carcinoma | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Parathyroid carcinoma | Annual incidence | <1 / 1 000 000 | United States | US | Exact |
| Parathyroid carcinoma | Annual incidence | <1 / 1 000 000 | United States | US | Exact |
| Parathyroid carcinoma | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 54 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Parathyroid carcinoma | 143 | Exact | Orphadata Science knowledge files, Product 1 |
| Parathyroid carcinoma | 143 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.